NASDAQ:VIVE

Viveve Medical Stock Forecast, Price & News

$2.93
-0.04 (-1.35 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.90
$3.09
50-Day Range
$2.40
$3.25
52-Week Range
$2.40
$14.40
Volume125,760 shs
Average Volume1.32 million shs
Market Capitalization$31.03 million
P/E RatioN/A
Dividend YieldN/A
Beta0.68
30 days | 90 days | 365 days | Advanced Chart
Receive VIVE News and Ratings via Email

Sign-up to receive the latest news and ratings for Viveve Medical and its competitors with MarketBeat's FREE daily newsletter.


Viveve Medical logo

About Viveve Medical

Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally. The company was founded in 2005 and is headquartered in Englewood, Colorado.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.73 out of 5 stars

Medical Sector

1307th out of 2,096 stocks

Electromedical Equipment Industry

34th out of 62 stocks

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Viveve Medical (NASDAQ:VIVE) Frequently Asked Questions

Is Viveve Medical a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viveve Medical in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Viveve Medical stock.
View analyst ratings for Viveve Medical
or view top-rated stocks.

What stocks does MarketBeat like better than Viveve Medical?

Wall Street analysts have given Viveve Medical a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Viveve Medical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Viveve Medical's next earnings date?

Viveve Medical is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Viveve Medical
.

How were Viveve Medical's earnings last quarter?

Viveve Medical, Inc. (NASDAQ:VIVE) announced its quarterly earnings data on Thursday, May, 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.51) by $0.29. Viveve Medical had a negative trailing twelve-month return on equity of 146.66% and a negative net margin of 400.27%.
View Viveve Medical's earnings history
.

How has Viveve Medical's stock been impacted by COVID-19?

Viveve Medical's stock was trading at $0.84 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VIVE shares have increased by 248.8% and is now trading at $2.93.
View which stocks have been most impacted by COVID-19
.

Who are Viveve Medical's key executives?

Viveve Medical's management team includes the following people:
  • Mr. Scott C. Durbin, CEO & Director (Age 52, Pay $635.05k)
  • Mr. Jim B. Robbins, Sr. VP of Fin. & Admin. and Principal Accounting & Financial Officer (Age 57, Pay $350.75k)
  • Ms. Debora A. Jorn M.B.A., Sr. Advisor to the CEO & Director (Age 63, Pay $35k)
  • Mr. Martin Kerber P.E., VP of Research, Devel. & Operations
  • Ms. Jeannie Swindle, Sr. Director of Corp. Communications
  • Mr. Jeff Sinclair, VP of International Sales
  • Mr. Gary Kaiser, VP of Global Marketing
  • Ms. Lori McMillan, VP of HR
  • Ms. Suzon D. Lommel, Sr. VP of Regulatory & Quality Affairs (Age 63)

Who are some of Viveve Medical's key competitors?

What other stocks do shareholders of Viveve Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viveve Medical investors own include Corbus Pharmaceuticals (CRBP), Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), SCYNEXIS (SCYX), Western Digital (WDC), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX) and Novavax (NVAX).

When did Viveve Medical IPO?

(VIVE) raised $13 million in an initial public offering on Tuesday, June 14th 2016. The company issued 1,600,000 shares at a price of $8.00 per share. Ladenburg Thalmann and Craig-Hallum Capital Group served as the underwriters for the IPO and Maxim Group was co-manager.

What is Viveve Medical's stock symbol?

Viveve Medical trades on the NASDAQ under the ticker symbol "VIVE."

Who are Viveve Medical's major shareholders?

Viveve Medical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.86%), Meitav Dash Investments Ltd. (0.53%), Virtu Financial LLC (0.42%), Citadel Advisors LLC (0.29%), Citadel Advisors LLC (0.28%) and UBS Group AG (0.24%).
View institutional ownership trends for Viveve Medical
.

Which institutional investors are buying Viveve Medical stock?

VIVE stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Meitav Dash Investments Ltd., Virtu Financial LLC, Citadel Advisors LLC, Citadel Advisors LLC, UBS Group AG, Geode Capital Management LLC, and Goldman Sachs Group Inc..
View insider buying and selling activity for Viveve Medical
or or view top insider-buying stocks.

How do I buy shares of Viveve Medical?

Shares of VIVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Viveve Medical's stock price today?

One share of VIVE stock can currently be purchased for approximately $2.93.

How much money does Viveve Medical make?

Viveve Medical has a market capitalization of $31.03 million and generates $5.48 million in revenue each year.

How many employees does Viveve Medical have?

Viveve Medical employs 42 workers across the globe.

What is Viveve Medical's official website?

The official website for Viveve Medical is www.viveve.com.

Where are Viveve Medical's headquarters?

Viveve Medical is headquartered at 345 INVERNESS DRIVE SOUTH BUILDING B SUITE 250, ENGLEWOOD CO, 80112.

How can I contact Viveve Medical?

Viveve Medical's mailing address is 345 INVERNESS DRIVE SOUTH BUILDING B SUITE 250, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-696-8100 or via email at [email protected]


This page was last updated on 6/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.